• Multiple sclerosis is a life threatening and very serious neurological disease that affects up to two million people worldwide.

• The specific cause of MS remains a complex mystery to modern medical science and to date tireless research efforts have revealed no cure.

• MS patients deserve the right to have the choice whether to take drugs to treat our disease or not to take drugs to treat our disease.

• If we choose drugs to treat our disease, then we want the right to choose which of the drugs to take.

• Patients who voluntarily enroll in professionally regulated human clinical drug study should always be granted an option to continue treatment if that drug has been found to be reasonably safe in early phase studies.

• It is extremely important for patients to be fully informed as to the pros and cons of each available treatment option for MS.

• We as MS patients have an obligation to ourselves and our families to ensure that we are properly and fully informed by our chosen medical professionals.

• Many of us have already injected ourselves for several years with one or more of the available drugs, and some of us have even had to resort to chemotherapy.

• Despite evidence that some MS treatments may provide marginal benefit and even have significant side effects our governments have rightfully given us the option to choose any of these available treatments.

• When an effective new drug exists that appears to be reasonably safe or effective, we as patients would like that drug to be disclosed to us and offered as an option for our treatment.

• We feel that any reasonably safe and effective treatment option should not be blocked or delayed by any government agency or competing companies in the global pharmaceutical industry that market available MS treatments.

• We feel the optimal decision for our treatment should be ours, after fully informing ourselves and consulting with our chosen physicians or professionals.

• The concerned pharmaceutical industry, professional health care providers, and government regulators should always offer the patient community adequate information to safely decide on any of the available treatment options.

• MS sufferers or their assigned caregivers always deserve well informed choice.

January 30, 2007

Archive